



Andreea Ioana Parosanu

EDUCAȚIE ȘI FORMARE PROFESIONALĂ

Medic specialist Oncologie Medicală

SUU Elias [02/2024 – În curs]

ESMO Examination 21 Octombrie 2023

Medic rezident Oncologie Medicală

SUU Elias [02/2019 – 01/2024]

Medic rezident Urologie

IC Fundeni [01/2018 – 02/2019]

Universitatea de Medicină și Farmacie Carol Davila, București

[2011 – 2017]

Colegiul Național Mircea cel Bătrân, Constanța

[2007 – 2011]

PUBLICAȚII

An unexpected cause of mild intermittent gross hematuria

Modoveanu O., Sinescu I., Parosanu A, et al, 2018 European Urology Supplements 17(12):e2672

The Importance of Dose Intensity When Administering Cytotoxic Chemotherapy in NSCLC—A Matter as Actual Now as in the Past,

Nitipir C., Orlov-Slavu C., Olaru M., Parosanu A.I. et al, Processes 8, no. 8: 936. 2020,

The Role of Multigene Assays in Adjuvant Treatment Decision for Early-Stage Breast Cancer,

Nitipir C., Parosanu A.I. Popa A.M., Iaciu C., 2020 Modern Medicine | 2020, Vol. 27, No. 2

News in Cancer-Related Pain Management

Nitipir C., Parosanu A.I., Alecu L., Popa A.M. et al. 2020 Modern Medicine | 2020, Vol. 27, No. 2

Stilul de viață și bolile oncologice, Medicina stilului de viață și bolile cronice,

Nitipir C., Orlov Slavu C., Parosanu A. I., Popa A. M. ed Medicală, 2020

Current perspectives in supportive care.

Parosanu A., Alecu L., Olrov-Slavu C., et al., Modern Medicine | 2020, Vol. 27, No. 4

Latest news in cancer-related fatigue

Nitipir C., Parosanu A. I., Alecu L., - Modern Medicine | 2020, Vol. 27, No. 4

Clinical Impact of the Administration of FOLFIRINOX Beyond Six Months in Advanced Pancreatic Adenocarcinoma: A Cohort Study

Nitipir C, Vrabie R, Parosanu A, et al., Cureus. 2021

Infection and reinfection with SARS-CoV-2 in cancer patients: A cohort study.

Nitipir C, Parosanu AI, Olaru M, Popa AM, Orlov-Slavu C. Exp Ther Med. 2022 Jun;23(6):399.

Desensitization Protocol to Carboplatin: A Technical Report.

Nitipir C, Parosanu AI, Olaru M, Popa AM, Orlov-Slavu, et al, Cureus 2022.

Neurological Paraneoplastic Syndromes: the Early Diagnosis of Lung Cancer.

Nitipir C, Parosanu AI, Modern Medicine, 2022 Volume 29, 2022, Volume 29, Issue 1

Correlation Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Programmed Death-Ligand 1 Expression as Prognostic Markers in NonSmall Cell Lung Cancer.

Nitipir C, Parosanu AI, et al. Cureus 14(7): e26843. doi:10.7759/cureus.26843

Use of Immune Checkpoint Inhibitors in Elderly Patients With Chronic Kidney Disease and Renal Cell Carcinoma Metastasis of the Parotid Gland: Case Report and Review of the Literature.

Parosanu AI, Nitipir. C., et al. doi:10.7759/cureus.28868

Prognostic Models for Renal Cell Carcinoma in the Era of Immune Checkpoint Therapy.

Parosanu A, Stanciu I, Pirlog C, et al. Cureus 14(10): e30821.

The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Patients with Metastatic Renal Cell Carcinoma.

Parosanu AI, Pirlog CF, Slavu CO,, et al. Curr Oncol. 2023 Feb 17;30(2):2457-2464.

Nivolumab Hypersensitivity Reactions a Myth or Reality in Solid Tumors-A Systematic Review of the Literature.

Pirlog CF, Parosanu AI, et al. Curr Oncol. 2022 Dec 2;29(12):9428-9436.

Prognostic Factors in First-line Metastatic Renal Cell Carcinoma: How to Improve the Prognostic Ability of the IMDC and MSKCC Score?.

Parosanu, A., et al. International Journal of Innovative Research in Medical Science, 2022, 7(12),

Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer—A Review of the Literature.

Stanciu I-M, Parosanu AI, Orlov-Slavu C, et al..Diagnostics. 2023

Tumor-to-Tumor Metastasis of Lung Cancer to Kidney Cancer: A Review of the Literature and Our Experience.

Baston C, Parosanu AI, Mihai M, et al.,Diagnostics (Basel). 2024 Mar 5;14(5):553.

The Role of KRAS Mutation in Colorectal Cancer-Associated Thrombosis.

Emilescu RA, Jinga M, Parosanu AI, Nitipir C. et al. Int J Mol Sci. 2023 Nov 29;

Restricted Mean Survival Time-Can It Be a New Tool in Assessing the Survival of Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors?

Pirlog CF, Costache R, Parosanu AI, et al. Diagnostics (Basel). 2023 May 29

Does the Rechallenge with Another CDK 4/6 Inhibitor in Breast Cancer Work? A Case Report and Literature Review. Medicina (Kaunas).

Stanciu IM, Pirlog CF, Anghel AW, Parosanu AI, et al..2023 Apr 1;59(4):696.

Challenges in the Diagnosis and Treatment of Oral Amelanotic Malignant Melanoma: A Case Report

Rosu O A, Tolea M I, Parosanu A I, et al. Cureus 16(4): e57875.

Second Primary Lung Cancer after Breast Cancer: Challenges and Approaches

BOGHICI M, PAROSANU AI, IACIU C, Modern Medicine, 2003 30. 157-160

PARTICIPARI LA CONGRESE SI SIMPOZIOANE

ESMO Preceptorship on Metastatic Bladder and Kidney Cancer - Multidisciplinary management, standards of care, therapeutic targets and future perspectives 2020

ESMO Virtual Preceptorship on Prostate Cancer - Multidisciplinary management, standards of care, therapeutic targets and future perspectives 2020

ESMO Virtual Preceptorship (November 2020) - Gastric Cancer

ESMO Virtual Preceptorship on Metastatic Bladder and Kidney Cancer (November 2020) - Multidisciplinary management, standards of care, therapeutic targets and future perspectives

A VIII-a conferinta a Colegiului Medicilor din Municipiul Bucuresti (25-27/07/22020)

Zilele Medicale si Stiintifice ale Institutului Oncologic Bucuresti (27-29/08/2020). Prezentare stiintifica-Perspective interdisciplinare in oncologie

Simpozion: Aspecte interdisciplinare in patologia urologica 24-25.06.2021

Conferinta Actualitati in sfera cancerelor renale, 23 martie 2022

Treatment challenges in HNSCC: where are we in 2022 (EMEAC HNSCC webinar) 29 March 2022

ESMO lung Cancer -Multidisciplinary management, standards of care and future perspectives 9-11 March 2022

European Lung Cancer Congres 30.03-02.04.2022

ESMO Gynecological Cancers Congres 2022 Valencia

ESMO Breast Cancer 3-5 May 2022, hybrid meeting Berlin, Germany,

Best of ASCO Conference 24-25.06.2022

Simpozionul de Oncologie Translationala Personalizata pentru combaterea cancerului . 22-24 septembrie 2022

Conferinta nationala IOB in startegia nationala si europeana de combatere a cancerului 19-21 mai 2022

The 9th Oncodigest virtual Conference (29-31/10/2020) ROSPEN (al XXIIIlea simpozion national de nutritie clinica si metabolism) 31 martie-2 aprilie 2022 Conferinta Oncohub sept 2022

A Xa conferinta Managementul bolilor pulmonare 4-5 iulie 2022

Congresul ONCOHELP 30iun-2iul 2022: Immunotherapy in urothelial cancers:Where do we stand?Future perspectives

ESMO Congress 2022 Paris, 9-13 September 2022

Conferinta: Actualitati in sfera cancerului de san, 22 Feb 2023

ESMO Congress 20-24 October 2023 Madrid

Summitul de Oncologie București 17 -18 noiembrie 2023

Actualitati in sfera cancerelor ginecologice 24 Aprilie 2024